Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Buy" by Analysts

Key Points

• Analysts hold a “Buy” consensus on Immuneering, with four buy ratings, two strong-buy ratings and one sell rating. The average 12-month price target is $17.50, well above the stock’s reported $5.33 price.
• Immuneering reported a quarterly loss of $0.27 per share, missing the consensus estimate by $0.01; analysts expect a full-year loss of $1.07 per share.
• Institutional investors own 67.65% of the company, with several firms recently increasing their positions. The clinical-stage biotech’s lead candidate, IRX-2, is in Phase 2 trials for painful diabetic peripheral neuropathy.

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have been given an average recommendation of "Buy" by the seven analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $17.50.

A number of research analysts have recently issued reports on IMRX shares. UBS Group set a $14.00 price objective on Immuneering in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immuneering in a research note on Wednesday, June 24th. Cantor Fitzgerald initiated coverage on Immuneering in a report on Wednesday, July 8th. They issued an "overweight" rating and a $17.00 target price for the company. Chardan Capital raised Immuneering to a "strong-buy" rating in a research note on Monday, August 3rd. Finally, Wall Street Zen cut Immuneering from a "hold" rating to a "sell" rating in a report on Monday, July 20th.

Immuneering Price Performance

Immuneering stock opened at $5.33 on Thursday. The firm has a market cap of $344.85 million, a P/E ratio of -5.12 and a beta of 0.43. Immuneering has a one year low of $3.25 and a one year high of $10.08. The stock's 50 day moving average is $4.69 and its 200 day moving average is $4.98.

Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.01). Equities analysts anticipate that Immuneering will post -1.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company's stock worth $776,000 after acquiring an additional 4,458 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Immuneering in the fourth quarter valued at $33,000. Southport Management L.L.C. raised its holdings in shares of Immuneering by 1.8% during the fourth quarter. Southport Management L.L.C. now owns 277,501 shares of the company's stock valued at $1,826,000 after purchasing an additional 5,000 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Immuneering by 46.4% during the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company's stock valued at $137,000 after purchasing an additional 6,196 shares during the period. Finally, LPL Financial LLC boosted its position in shares of Immuneering by 30.0% during the 4th quarter. LPL Financial LLC now owns 29,125 shares of the company's stock worth $192,000 after purchasing an additional 6,725 shares in the last quarter. Institutional investors and hedge funds own 67.65% of the company's stock.

Immuneering Company Profile

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source